Salute e Benessere
SciBase reaches milestone with over 300,000 patients tested with Nevisense
Designed to augment the capabilities of traditional dermoscopy, leverages the unique electrical properties of skin tissue to provide clinicians with objective data to support their clinical assessment. The device delivers that help guide risk-aligned management strategies for patients with potentially malignant skin lesions.
With and studies, Nevisense has been shown to improve diagnostic accuracy and support improved patient outcomes. Its non-invasive method enables more efficient biopsy management decisions while ensuring that high-risk cases receive timely attention.
As the global burden of melanoma continues to rise, technologies like Nevisense are proving invaluable in aiding early detection efforts-where outcomes are most favorable.
Pia Renaudin , CEO, tel. +46732069802, e-mail: pia.renaudin@scibase.com
DNB Carnegie Investment Bank AB (publ) Phone: +46 (0)73 856 42 65 E-mail: certifiedadviser@carnegie.se
This information was brought to you by Cision http://news.cision.com.
https://news.cision.com/scibase/r/scibase-reaches-milestone-with-over-300-000-patients-tested-with-nevisense,c4155900
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/scibase-reaches-milestone-with-over-300-000-patients-tested-with-nevisense-302465743.html